Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

NCT07591649 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Adult AML
Refractory AML
Acute Myelogenous Leukemia

Interventions

BIOLOGICAL: AdaptNK
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: IL-2

Sponsor

Masonic Cancer Center, University of Minnesota